The role of mRNA m\textsuperscript{6}A methylation in the nervous system

Jiashuo Li, Xinxin Yang, Zhipeng Qi, Yanqi Sang, Yanan Liu, Bin Xu, Wei Liu, Zhaofa Xu and Yu Deng*

Abstract

Epitranscriptomics, also known as "RNA epigenetics," is a chemical modification for RNA regulation. Ribonucleic acid (RNA) methylation is considered to be a major discovery following the deoxyribonucleic acid (DNA) and histone methylation. Messenger RNA (mRNA) methylation modification accounts for more than 60% of all RNA modifications, and N6-methyladenosine (m\textsuperscript{6}A) is known as one of the most common types of eukaryotic mRNA methylation modifications in current. The m\textsuperscript{6}A modification is a dynamic reversible modification, which can directly or indirectly affect biological processes, such as RNA degradation, translation, and splicing, and can play important biological roles in vivo. This article introduces the mRNA m\textsuperscript{6}A methylation modification enzymes and binding proteins, and reviews the research progress and related mechanisms of the role of mRNA m\textsuperscript{6}A methylation in the nervous system from the aspects of neural stem cells, learning and memory, brain development, axon growth, and glioblastoma.

Keywords: Epitranscriptomics, N6-methyladenosine (m\textsuperscript{6}A), Methyltransferase, Demethylase, Binding protein, Nervous system

Background

Epitranscriptomics, also known as “RNA epigenetics,” is a chemical modification for RNA regulation [1]. According to its function, RNA can be divided into two broad categories, including encoding protein mRNA and non-coding RNA. With the deep research of epitranscriptomics, the researchers found methylation modification on mRNA, which is involved in the regulation of eukaryotic gene expression [2–4].

The mRNA is a type of RNA with genetic information synthesized by DNA transcription, which acts as a template in protein synthesis and determines the amino acid sequence of the peptide chain [5]. It is an important RNA in the human body. The methylation is the process of catalytically transferring a methyl group from an active methyl compound such as S-adenosylmethionine (SAM) to another compound, which can chemically modify certain proteins or nucleic acids to form a methylated product [6]. In biological systems, methylation influences heavy metal modification, regulation of gene expression, regulation of protein function, RNA processing, etc. [7]. At the early 1970s, scientists discovered the presence of the methylation modification in mRNA [8, 9]. The mRNA methylation modification mainly located in the nitrogen atom of the base group to form m\textsuperscript{6}A, which is enriched in long exons and overrepresented in transcripts with alternative splicing variants [10]. The mRNA methylation modifications also include 5-methylcytosine (m\textsuperscript{5}C), N1-methyladenosine (m\textsuperscript{1}A), 5-hydroxymethylcytosine (5hmC), N6, 2′-O-dimethyladenosine (m\textsuperscript{6}Am), 7-methylguanine (m\textsuperscript{7}G) (Fig. 1). These modifications can affect regulation of various biological processes, such as RNA stability and mRNA translation, and abnormal mRNA methylation is linked to many diseases [11].

Main text

Discovery and distribution of m\textsuperscript{6}A

The m\textsuperscript{6}A is the most common and abundant methylation modification in mRNA [12, 13]. In 1974, Desrosie used the polyadenosinic acid (PolyA) structure in eukaryotes, to discover the methylation status of mRNA in hepatoma cells, and found that the main methylation modification in mRNA was m\textsuperscript{6}A (approximately 80%) [8]. In addition,
the presence of $m^6A$ was also detected in a variety of eukaryotes and viral mRNA [14].

In mammals, $m^6A$ is widely distributed in multiple tissues. Studies by Meyer showed that $m^6A$ expression was higher in liver, kidney and brain than in other tissues. It has also been found that the content of $m^6A$ is very different in various cancer cell lines [15]. With the help of high-throughput sequencing technology, a rough $m^6A$ modification map has been obtained. Meyer studied the $m^6A$ modification in mouse brain and found that it was mainly distributed inside the gene (94.8%), where the proportions in the protein coding region (CDS), untranslated regions (UTRs) and introns are 50.9%, 41.9%, and 2.0% respectively [16]. The $m^6A$ in the UTRs region tends to be enriched in the 3′UTR, while in the CDS region it is mainly enriched near the stop codon [17]. The $m^6A$ modification occurs mainly on the adenine in the RRACH sequence, where R is guanine or adenine, and H is uracil, adenine or cytosine [18] (Fig. 2).

### mRNA $m^6A$ methylation modification enzyme

The methylation modification of $m^6A$ has been proved to be reversible, as it involves both methyltransferase and demethylase. The main role of methyltransferases is to catalyze the $m^6A$ modification of mRNA, while demethylases act on demethylation of bases that have had $m^6A$ modification [19, 20].

### $m^6A$ methyltransferase

The $m^6A$ methyltransferase, also known as “Writers”, is an important kind of catalytic enzymes [21]. Methyltransferase like 3/14 (METTL3/14), Wilms’ tumour 1-associating protein (WTAP), KIAA1429 and RNA binding motifs protein 15/15B (RB15/15B) are core components of the $m^6A$ methyltransferase, which form complexes that work together to perform catalytic functions. Besides, E3 ubiquitin-protein ligase Hakai (HAKAI) and zinc finger CCCH-type containing 13 (ZC3H13) are also the part of the mRNA methyltransferase complex.

The METTL3 is identified as a SAM-binding component of the complex and has its own catalytic ability, which is highly conserved in eukaryotes [22]. METTL14 is closely homologous to METTL3. It does not bind to the SAM domain and does not with independently $m^6A$ methyltransferase function. Biochemical characterization has shown that METTL3 and METTL14 proteins form a stable complex with a stoichiometric ratio of 1:1, and the methylation activity of the complex is higher than that of METTL3 alone. Among them, METTL3 is a catalytically active subunit, and METTL14 plays a key role in substrate identification [23, 24].

The WTAP is a regulatory subunit of the $m^6A$ methyltransferase complex, which can interact with METTL3 and METTL14. Knocking out WTAP can significantly reduce the $m^6A$ peak in cellular mRNA, even more effective than knocking down METTL3 or METTL14. The WTAP-bound gene has a change in alternative splicing patterns [25].

The KIAA1429, also known as vir-like $m^6A$ methyltransferase associated (VIRMA), is a homologous protein of the Virilizer protein in Drosophila, which is closely related to the methyltransferase complex. The N-terminus of KIAA1429 has the ability to gather methyltransferase-catalyzed core METTL3/METTL14/WTAP that can achieve the regulation of fixed-point $m^6A$ levels on mRNA [26].

It was identified by co-immunoprecipitation that the binding of RBM15/15B at the RRACH sequence site is three to fourfold higher than that at the non-methylation site. Knocking down the RBM15 or RBM15B alone can reduce the $m^6A$ levels in cellular mRNA, and
knocking down both RBM15 and RBM15B can result in a significant decrease of the m^6^A levels in mRNA [27].

The HAKAI, also known as CBL proto-oncogene like 1 (CBLL1), is an E3 ubiquitin ligase. Down-regulation of the HAKAI in Arabidopsis can result in a decrease in m^6^A level [28]. ZC3H13 is also an important component of the methyltransferase complex and is key to anchor the complex in the nucleus [29]. Methyltransferase like 16 (METTL16) is a m^6^A methyltransferase of the mRNA precursor that maintains SAM homeostasis by regulating alternative splicing of methionine adenosyltransferase II alpha (MAT2a) [30–32].

m^6^A demethylase

The m^6^A demethylase, also known as the “Erasers”. In eukaryotes, m^6^A demethylases are fat mass and obesity-associated protein (FTO) and alkB homolog 5 (alkB homolog 5, ALKBH5). In Arabidopsis, the alkB homolog 10B (ALKBH10B) has also been found as a m^6^A demethylase of mRNA.

The FTO also known as alkB homolog 9 (ALKBH9), which is a member of the alkB protein family and associated with obesity. FTO is the first-discovered RNA demethylase. The long stem loop domain at the C-terminus of FTO enables the FTO proteins demethylate [33, 34].

The ALKBH5 is another protein of the AlkB family and plays an important regulatory role in biological processes, such as mRNA processing. The ALKBH5 is similar to FTO and is also a Fe^{2+} and α-Ketoglutaric acid-dependent non-heme oxygenase. The ALKBH5 has an alanine-rich region at the N-terminus and a unique coiled-coil structure. It only demethylates the m^6^A modification on single-stranded RNA/DNA, and the catalytic reaction removes methyl groups directly from m^6^A-methylated adenosine instead of oxidative demethylation [35, 36].

The ALKBH10B is an m^6^A demethylase of mRNA in Arabidopsis, which regulates mRNA stability and affects the transformation of Arabidopsis from vegetative growth to reproductive growth [37].

mRNA m^6^A methylation binding protein

The m^6^A-modified mRNA that performs a specific biological function requires a specific RNA-binding protein-readers. Binding assays of RNA protein in vitro have identified a variety of binding proteins, including YTH domain containing RNA binding protein (YTP), heterogeneous nuclear ribonucleoprotein (hnRNP), eukaryotic initiation factor 3 (eIF3), Insulin-like growth factor 2 mRNA-binding protein (IGF2BP) and Proline rich coiled-coil 2A (Prrc2A). The functions of these binding proteins mainly include specific binding to the m^6^A methylation region, weakening the homologous binding to RNA reading proteins, and altering the secondary structure of RNA to alter protein–RNA interaction [38, 39].

YTH domain containing RNA binding protein include YTH domain-containing family protein 1/2/3 (YTHDF1/2/3) and YTH domain-containing protein 1/2 (YTHDC1/2). YTHDF1/2/3 and YTHDC2 specifically recognize the m^6^A-modified mRNA in the cytoplasm, while the recognizing sites of YTHDC1 are mainly in the nucleus. These proteins all have a YTH domain at the C-terminus. They are capable of overlapping with the m^6^A RRACH fragment to mediate RNA-specific binding, while its proline/glutamine/asparagine enrichment (P/Q/N-rich) domain is related to subcellular localization [40, 41].

YTHDF1 is combined with translation initiation factors and ribosomes, improving the translation efficiency. YTHDF2 is the first-discovered binding protein. Specifically, it recognizes and binds m^6^A-containing RNAs, and regulates mRNA stability [42, 43]. YTHDF3 promotes the translation of mRNA and regulates the mRNA stability. YTHDF3 and YTHDF1 coordinately control during translation [44, 45]. YTHDC1 regulates the mRNA cleavage by recruiting splicing factors [46–48]. YTHDC2 accelerates the degradation of the modified mRNA and enhances the translation of the corresponding protein by recognizing m^6^A [49].

The hnRNP is a group of RNA-binding proteins that contain nearly 30 nucleic acid-binding proteins with molecular weights ranging from 30 to 120 kDa, which can interact with each other to form the complex, where A1, A2, B1, B2, C1 and C2 are the main core components. Heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1) is capable of specifically recognizing the m^6^A modifications on transcripts, activating downstream variable shear events of partial genes [50, 51]. Heterogeneous nuclear ribonucleoprotein C (HNRNPC) is responsible for recognizing the m^6^A modifying group and mediating the processing of the mRNA precursor in the nucleus, affecting the abundance and alternative splicing of target transcripts. The m^6^A can increase the accessibility of its surrounding RNA sequences binding to heterogeneous nuclear ribonucleoprotein G (HNRNPG). In the transcriptome, the m^6^A site regulates RNA-HNRNPG interactions to alter target mRNA expression and alternative splicing patterns [52].

In mammalian cells, elF3 is the largest eukaryotic initiation factor and plays a key role in the initiation of eukaryotic translation. It is able to directly bind to the 5’UTR m^6^A of mRNA, thereby facilitating translation of mRNA. IGF2BP protein is a unique m^6^A reader. The family mainly includes IGF2BP1/2/3. IGF2BP can make
the target gene and corresponding translation more stable [53]. Prcc2a is a new m^6^A reader that stabilizes mRNA expression by binding to a consensus GGACU motif in the CDS region in an m^6^A-dependent manner [54] (Fig. 3).

**Neurobiological function of mRNA m^6^A methylation**
Sequencing results have showed that the level of RNA m^6^A modification increase significantly during embryogenesis [55–58]. Compared to other organs or tissues, the overall level of m^6^A in the head is significantly higher. This suggests that the mRNA m^6^A modification has potential neurobiological functions in the nervous system and is worthy of further study [59–63].

**Effect of m^6^A on neural stem cells**
Neural stem cells maintain cell populations through self-renewal, and can differentiate into various nerve cells such as neurons, astrocytes, and oligodendrocytes [64–67]. A number of studies have shown that the mRNA m^6^A modification can affect the self-renewal and differentiation of neural stem cells [68–70]. These new findings will promote stem cell therapy and gene-targeted therapy for neurological diseases.

Inactivation of Mettl3 in mouse and human embryonic stem cells leads to a decrease in m^6^A, and severely impairs the transition of neurons from self-renewal to differentiation. The knockout of Mettl3 can cause early embryonic lethality and impair the formation of mature neurons in the embryoid body [58, 71]. Wang et al. found that when knocking out Mettl14 in embryonic neural stem cells in a mouse model, the proliferation of neural stem cells was significantly reduced and differentiated prematurely. It indicates that m^6^A can promote the proliferation of neural stem cells and prevent premature differentiation of cells, thus ensuring the reserve of neural stem cell bank [72, 73]. Mettl14 and Mettl3 can participate in neurogenesis by regulating the cell cycle progression of cortical neural stem cells, which acts in a m^6^A-dependent way [74]. The SMAD2/3 protein binds to the METTL3-METTL14-WTAP complex and promotes the differentiation of embryonic stem cells into neuroendodermal cells [75].

The Ythdf2-mediated m^6^A mRNA clearance has a regulatory effect on neurodevelopment in mice. Proliferation and differentiation of neural stem cells are seriously affected by the deletion of embryonic Ythdf2 [76].

**Effect of m^6^A on learning and memory**
In the emerging field of epitranscriptomic mechanisms, mRNA m^6^A modification has potential role in learning and memory [77]. It regulates physiological and stress-induced behavior in the adult mammalian brain, and augments the strength of weak memories [78–80]. As a newly identified element in the region-specific gene regulatory network in the mouse brain, mRNA m^6^A modification plays a vital role in the death of dopaminergic neuron [81, 82].

Mettl3-mediated RNA m^6^A modification has the direct effect on regulating hippocampal-dependent long-term memory formation. The decrease of Mettl3 in the mice hippocampus may reduce its memory consolidation, and adequate training or restoration would restore the ability of learn and memory. The abundance of Mettl3 in the

![Fig. 3 mRNA m^6^A methylation-associated protein](image-url)
hippocampus of wild-type mice is positively correlated with learning efficiency, and the overexpression of Mettl3 can significantly enhance the long-term memory consolidation [83]. METTL14 is critical for striatum function and transcriptional regulation of learning epitopes. In cell experiments, the deletion of METTL14 reduces striatum m6A levels without altering cell number or morphology, increases neuronal excitability and severely impaired striatal-mediated behavior [84].

Fto can regulate the activity of dopaminergic midbrain circuits. Inactivation of the Fto gene weakens neuronal activity and behavioral responses that are dependent on dopamine receptor type 2 (D2R) and type 3 (D3R) (collectively D2-like receptors) [85]. FTO also regulates dopaminergic neurotransmission deficits caused by arsenite [86]. Walters [87] has found that Fto plays an important role in the formation of mouse hippocampal-dependent memory. The decrease in Fto protein observed shortly after the situational fear reflex indicates that Fto typically limits memory formation. The m6A is regulated in the activity-dependent way in the adult brain, and may fine-tune mRNA turnover during memory-related processes [88]. When knocking out the Fto gene in the prefrontal cortex of mice, the intensity of m6A on several fear-related genes in neurons increases significantly, and the knockdown of Fto further enhances the consolidation of fear memory [89]. FTO plays important roles in learning and memory. The loss of FTO led to the altered expression of several key components of the brain derived neurotrophic factor pathway that were marked by m6A [90].

In the adult mouse hippocampus, the m6A binding protein Ythdf1 can promote neuronal stimulation of protein translation of target transcripts, thereby facilitating learning and memory. Mice with a genetic deletion of Ythdf1 have showed the deficits of learning and memory, impaired hippocampal synaptic transmission and long-term potentiation [91]. Prrrc2a controls the specification and myelination of oligodendrocyte, and Prrc2a knock-out induces cognitive defects in a mouse model [54].

Effect of m6A on brain development
Widespread and dynamic m6A methylation were identified in the developing mouse cerebellum. RNA m6A methylation is controlled in a precise spatiotemporal manner and participates in the regulation of postnatal development of the mouse cerebellum [92, 93].

Specific inactivation of Mettl3 in mouse nervous system causes severe developmental defects in the brain. Mettl3-mediated m6A participates in cerebellar development by controlling mRNA stability of genes involved in cerebellar development and apoptosis [94].

Under the low pressure and hypoxia, the level of RNA m6A methylation in the cerebellar of Alkbh5-deficient mouse is imbalanced, which leads to an increase in the efficiency of extranuclear RNA excretion and a significant change in cerebellar phenotype, including neuronal structural disorder, abnormal cell proliferation and differentiation, and other phenotypes [92].

Effect of m6A on synaptic growth
The m6A modification plays a key role in synaptic regeneration of mature mouse neurons. Increased m6A in somatic neurons alters the transcriptome response to synaptic plasticity [77, 89]. The m6A methylation of neurological function-related genes in the hippocampus of human immunodeficiency virus transgenic rats is significantly different, suggesting synaptic damage and neurodegeneration [95]. The m6A methylation of synaptic mRNAs critically contribute to synaptic function in healthy adult mouse forebrains [96].

Deletion of Mettl14 reduces functional axonal regeneration in the peripheral nervous system of the body. After knockdown of Mettl14, the axonal regeneration of retinal ganglion neurons in the central nervous system is also diminished [97].

The m6A modification can affect axon growth by regulating local translation of mRNA in neuronal axons. FTO is highly expressed in axons of neurons. Local translation in axons plays an important role in neurodevelopment, including axon guidance, axon growth, and neuronal specifications [90, 98].

The mRNA m6A modification of synaptic plays a key role in synaptic function. After knocking out the dendritic positioning readers Ythdf1 and Ythdf3 in cultured hippocampal neurons, m6A-reader-deficient neurons have abnormal spine morphology and the spines are reduced. Knocking out the Ythdf1 gene of mouse, in the peripheral and peripheral nervous system, functional axon regeneration is reduced [97, 99]. The neurons of YTHDF2−/− could not produce normal synapses [76].

Effect of m6A on glioblastoma
Several studies have revealed the role of m6A withers and erasers in glioblastoma. Changes of the m6A level in glioblastoma stem cell-like cells (GSC) severely affect the growth, self-renewal and development of tumor. The mRNA m6A methylation is expected to be a new target for the treatment of glioblastoma [100].

Decreasing the m6A levels by knocking down METTL3 and/or METTL14 enhance growth and self-renewal of GSCs in vitro, and promote the ability of GSCs to form brain tumors in vivo. The Mettl3-mediated m6A modification plays a key role in neurosphere maintenance and glioma cell dedifferentiation [101–103]. Ethyl form of methylbenzoic acid (MA2) is a selective inhibitor of FTO, which can significantly inhibit tumor progression.
and prolong the lifespan of GSC mice. Therefore, The Fto may play a key carcinogenic role in GSC self-renewal and is required for the development of glioblastoma [101]. ALKBH5 is able to maintain stem cell in malignant glioma cells, and ALKBH5-mediated m^6^A modification on forkhead box M1 (FOXM1) mRNA is involved in the maintenance of tumor stem cell. High expression of ALKBH5 predicts poor prognosis in glioblastoma patients [104, 105] (Table 1).

### Conclusion

In summary, the mRNA methylation is an important epitranscriptomic modification and the m^6^A is highly expressed in the brain. The mRNA m^6^A methylation has a wide range of effects on the nervous system, and plays an important part in self-renewal of neural stem cells, learning memory, brain development, synaptic growth and proliferation of glioma cells. This new regulatory system will promote targeted therapy for neurological diseases.

However, mRNA m^6^A methylation is a relatively new field and many problems remain unknown. Up till now, all of the demethylases found belong to the AlkB family, and whether other proteins in the AlkB family are also involved in mRNA demethylation is worthy for further study. HNRNPA1, HNRNPG and HNRNPM play a key role in the methylation of protein arginine. These proteins are similar to HNRNPA2B1 and HNRNPC, and belong to the hnRNP binding protein family. It is worth exploring its role in mRNA m^6^A methylation.

Variations in the FTO gene can not only regulate D2R-dependent reward learning [106–108], but also affect nerve adjust food visual, produce more frequent rewards [109–111], affect the control of mood and impulse [112–114], and affect obesity by regulating brain signaling pathways [115, 116]. The homozygous mutation of FTO gene can reduce the brain capacity of healthy elderly people, increase the susceptibility to brain atrophy during aging, and even affect the brain volume of adolescents [117, 118]. The genetic polymorphism of FTO is related to attention-deficit/hyperactivity disorder [119–124]. Whether it is as demethylase that affects these diseases, is worthy of further study.

The genetic polymorphism of ZC3H13 is associated with schizophrenic. Nito, another member of the m^6^A methyltransferase complex in Drosophila, called RBM15 in human, controls the axonal growth and differentiation and regulates the synapse formation through neuronal activity. Whether human ZC3H13 and RBM15 genes have the effect on synaptic growth, is worthy of further study.

To study the methylation mechanism of mRNA m^6^A and find potential targets for treatment, it is hopeful to develop inhibitors or agonists of related proteins for clinical treatment in the future.

### Abbreviations

- Shmnc: 5-hydroxymethylcytosine; ADHD: attention-deficit/hyperactivity disorder; ALKBH5/9/10B: alkB homolog 5/9/10B; CBLL1: CBL proto-oncopogene like 1; CDS: coding region; D2/3R: dopamine receptor type 2/3; DNA: deoxyribonucleic acid; eIF3: eukaryotic initiation factor 3; FOXM1: forkhead box M1; FTO: fat mass and obesity-associated protein; GSC: glioblastoma stem cell-like cells; HAKAI: E3 ubiquitin-protein ligase Haka1; hmrnnp: heterogeneous nuclear ribonucleoprotein; HNRNPA2B1/C/G: heterogeneous nuclear ribonucleoprotein A2B1/C/G; Igf2bp: insulin-like growth factor 2 mRNA-binding protein; m^6^A: N1-methyladenosine; m^5^C: 5-methylcytosine; m^6^A: N6-methyladenosine; m^6^Am: N6,2'-O-dimethyladenosine; m^6^G: 7-methylguanine; MA2: methylbenzoic acid; MAT2a: methionine adenosyltransferase II Alpha; METTL3/14/16: methyltransferase like 3/14/16; mRNA: messenger RNA; P/Q/N-rich: proline/glutamine/asparagine enrichment; PolyA: polyadenosinic acid; Prrc2a: proline rich-collared-coil 2A; RBM15/15B: RNA binding motifs protein 15/15B; RNA: ribonucleic acid; SAM: S-adenosylmethionine; UTRs: untranslated regions; VIRMA: vir-like mRNA methyltransferase associated; WTAP: Wilms’ tumour 1-associating protein; YTHDC1/2: YTH domain-containing protein 1/2; YTHDF1/F2/3: YTH domain-containing family protein 1/2/3; YTP: YTH domain containing RNA binding protein; ZC3H13: zinc finger CCCH-type containing 13.

### Acknowledgements

We would like to acknowledge Qixue Li, Fengdi Wu, Minghui Li, Xianchao Du, Bingchen Liu and Haiying Wang for their advice.

### Authors’ contributions

Each author substantially contributed to the review. JL: conception and design, drafting the review; XY, ZQ, YS, YL, BX, WL and ZX: revising the manuscript; YD: conception and design, revising it critically for important intellectual content, and final approval of the version to be published. All authors read and approved the final manuscript.

### Funding

We gratefully acknowledge funding from the Basic Research Fund of Young Program of Higher Education of Liaoning Province (Grant No. QNK201735), the National Natural Science Foundation of China (Grant No. 81302406) and the Funds for Distinguished Young Scientists in School of Public Health, China Medical University.

### Availability of data and materials

Not applicable.

### Ethics approval and consent to participate

Not applicable.

### Consent for publication

Written informed consent for publication was obtained from all participants.

### Competing interests

The authors declare that they have no competing interests.

---

**Table 1 Neurobiological functions of mRNA m^6^A methylation**

| Neurological disease | Related enzymes and proteins |
|---------------------|-----------------------------|
| Neuronal stem cell  | METTL3, METTL14 and YTHDF2  |
| Learning memory     | METTL3, METTL14, FTO, YTHDF1 and Prrc2a |
| Brain development   | METTL3 and ALKBH5           |
| Synaptic growth     | METTL14, FTO, YTHDF1, YTHDF2 and YTHDF3 |
| Glioblastoma        | METTL3, METTL14, FTO and ALKBH5 |
References

1. Roundtree IA, He C. RNA epigenetics–chemical messages for posttranscriptional gene regulation. Curr Opin Chem Biol. 2016;30:46–51. https://doi.org/10.1016/j.cbpa.2015.10.024.

2. Zheng G, Dahl JA, Niu Y, Fu Y, Klungland A, Yang YG, et al. Sprouts of RNA epigenetics. RNA Biol. 2013;10:915–8. https://doi.org/10.4161/rna.24711.

3. Liu N, Pan T. RNA epigenetics. Transl. Res. 2015;165:28–35. https://doi.org/10.1016/j.trsl.2014.04.003.

4. Nachtergaele S, He C. Chemical modifications in the life of an mRNA transcript. Annu Rev Genet. 2018;52:349–72. https://doi.org/10.1146/annurev-genet-120417-031522.

5. Roignant JY, Soller M. m6A in mRNA: an ancient mechanism for fine-tuning gene expression. Trends Genet. 2015;31:380–90. https://doi.org/10.1016/j.tig.2014.07.003.

6. Tuck MT. The formation of internal 6-methyladenine residues in eucaryotic messenger RNA. Int J Biochem. 1992;24:379–86. https://doi.org/10.1016/0192-4281(92)90028-y.

7. Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, et al. N6-methyladenosine modulates messenger RNA translation efficiency. Cell. 2015;161:1388–99. https://doi.org/10.1016/j.cell.2015.05.014.

8. Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger-RNA from Novikoff hepatoma-cells. Proc Natl Acad Sci USA. 1974;71:3971–5. https://doi.org/10.1073/pnas.71.10.3971.

9. Canaani D, Kahana C, Lavi S, Groner Y. Identification and mapping of N6-methyladenosine containing sequences in simian virus 40 RNA. Nucleic Acids Res. 1979;6:2870–99. https://doi.org/10.1093/ nar/6.8.2879.

10. Zhao BS, Nachtergaele S, Roundtree IA, He C. Our views of dynamic N6-methyladenosine RNA methylation. RNA. 2014;20:268–72. https://doi.org/10.1261/rna.064295.117.

11. Patel DP, Chen CK, Pickering BF, Chow A, Jackson C, Guttman M, et al. m6A RNA methylation promotes XIST-mediated transcriptional repression. Cell. 2015;161:1388–99. https://doi.org/10.1016/j.cell.2015.05.014.

12. Shi H, Wei J, He C. Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol Cell. 2016;62:335–45. https://doi.org/10.1016/j.molcel.2016.03.021.

13. Knuckles P, Lence T, Haußmann IU, Jacob D, Kreim N, Carl SH, et al. Zc3h13/Flac is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Speninto to the m6A RNA methylation complex. Dev. Genes. 2018;38:415–29. https://doi.org/10.1011/ijdg/2018.02.015.

14. Shima H, Matsumoto M, Ishigami Y, Ebina M, Muto A, Sato Y, et al. S-Adenosylmethionine synthesis is regulated by selective N6-adenosine methylation and mRNA degradation involving METTL16 and YTHDC1. Cell Rep. 2017;21:3354–63. https://doi.org/10.1016/j.celrep.2017.11.092.

15. Cao G, Li HB, Yin Z, Favello RA. Recent advances in dynamic m6A RNA modification. Open Biol. 2014;4:616003. https://doi.org/10.1098/rsob.160003.

16. Meyer KD, Jaffrey SR. The dynamic epitranscriptome: N6-methyladenosine and gene expression control. Nat Rev Mol Cell Biol. 2014;15(5):313–26. https://doi.org/10.1038/nrm3785.

17. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. Cell. 2012;149:1635–46. https://doi.org/10.1016/j.cell.2012.05.003.

18. Ke S, Aleluu EA, Mertens C, Gantman EC, Fak JJ, Mele A, et al. A majority of m6A residues are in the last exons, allowing for potential 3′ UTR regulation. Genes Dev. 2015;29:2037–53. https://doi.org/10.1101/gad.269415.115.

19. Deng X, Su R, Weng H, Huang H, Li Z, Chen J. RNA N6-methyladenosine modification in cancers: current status and perspectives. Cell Res. 2018;28:555–66. https://doi.org/10.1038/s41422-018-0034-6.

20. Yang Y, Hu PJ, Chen YS, Yang YG. Dynamic transcriptional m6A decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018;28:616–24. https://doi.org/10.1038/s41422-018-0040-8.

21. Meyer KD, Jaffrey SR. Rethinking m6A readers, writers, and erasers. Annu Rev Cell Dev Biol. 2017;33:319–42. https://doi.org/10.1146/annurev-cellbio-100816-060058.

22. Liu S, Choe J, Du P, Triboulet R, Gregory RI. The m6A methyltransferase METTL3 promotes translation in human cancer cells. Mol Cell. 2016;62:335–45. https://doi.org/10.1016/j.molcel.2016.03.021.

23. Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10:93–5. https://doi.org/10.1038/nchembio.1432.

24. Yang X, Feng J, Xue Y, Guan Z, Zhang D, Liu Z, et al. Corrigendum: structural basis of N6-adenosine methylation by the METTL3-METTL14 complex. Nature. 2017;542:260. https://doi.org/10.1038/ nature21073.

25. Li et al. Cell Biosci (2019) 9:66

26. Deng X, Su R, Weng H, Huang H, Li Z, Chen J. RNA N6-methyladenosine demethylase affecting arabidopsis floral transition. Plant Cell. 2017;29:2995–3011. https://doi.org/10.1105/tpc.16.00912.

27. Wu B, Li H, Huang Y, Ma J, Min J. Readers, writers and erasers of N6-methylated adenosine modification. Curr Opin Struct Biol. 2017;47:67–76. https://doi.org/10.1016/j.sbi.2017.05.011.

28. Adhikari S, Xiao W, Zhao YL, Yang YG. m6A: signaling for mRNA splicing. RNA Biol. 2016;13:756–9. https://doi.org/10.1080/15476962.2016.1210268.

29. Liao S, Sun H, Xu C. YTH domain family: a family of N6-methyladenosine (m6A) readers. Genomics Proteom Bioinform. 2018;16:99–107. https://doi.org/10.18390/gpb.2018.04.002.
41. Patil DP, Pickering BF, Jaffrey SR. Reading m6A in the transcriptome: m6A-binding proteins. Trends Cell Biol. 2018;28:113–27. https://doi.org/10.1016/j.tcb.2017.10.001.

42. Du H, Zhao Y, He J, Zhang Y, Xi H, Liu M, et al. YTHDF2 destabilizes m6A-containing RNA through direct recruitment of the CCR4–NOT deadenylase complex. Nat Commun. 2016;7:1262. https://doi.org/10.1038/ncomms12626.

43. Zhu T, Roundtree IA, Wang P, Wang X, Wang L, Sun C, et al. Crystal structure of the YTH domain of YTHDF2 reveals mechanism for recognition of N6-methyladenosine. Cell Res. 2014;24:1493–6. https://doi.org/10.1038/cr.2014.152.

44. Li A, Chen YS, Ping XL, Yang X, Xiao W, Yang Y, et al. Cytoplasmic m6A reader YTHDF3 promotes mRNA translation. Cell Res. 2017;27:444–7. https://doi.org/10.1038/cr.2017.10.

45. Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu PJ, et al. YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA. Cell Res. 2017;27:315–28. https://doi.org/10.1038/cr.2017.15.

46. Xiao W, Adhikari S, Dahal U, Chen YS, Yao Y, Sun BF, et al. Nuclear m6A reader YTHDC1 regulates mRNA splicing. Mol Cell. 2016;61:507–19. https://doi.org/10.1016/j.molcel.2016.01.012.

47. Roundtree IA, Luo GZ, Zhang Z, Wang X, Zhou T, Cui Y, et al. YTHDC1 mediates nuclear export of N6-methyladenosine methylated mRNAs. Elife. 2017;6:e31311. https://doi.org/10.7554/eLife.31311.

48. Hsu PJ, Zhu Y, Ma H, Guo Y, Shi X, Liu Y, et al. Ythdc2 is an N6-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017;27:1115–27. https://doi.org/10.1038/cr.2017.99.

49. Alarcon CR, Goodarzi H, Lee H, Liu X, Tavazoie S, Tavazoie SF. HNRNPs A1 and A2/B1. Genes Dev. 2016;30:1070–85. https://doi.org/10.1101/gad.13614.

50. Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, et al. Stem cells. m6A mRNA methylation facilitates temporal control of mammalian cortical neurogenesis. Cell. 2017;171:877–99. https://doi.org/10.1016/j.cell.2017.09.003.

51. Geula S, Moshitch-Moshkovitz S, Dominissini D, Mansour AA, Kol N, Salmon-Dixon M, et al. Stem cells. m6A mRNA methylation facilitates resolution of naive pluripotency toward differentiation. Science. 2015;347:1002–6. https://doi.org/10.1126/science.1261417.

52. Yoon KJ, Ringeling FR, Vissers C, Jacob F, Pokras M, Jimenez-Cyrus D, et al. Temporal control of mammalian cortical neurogenesis by m6A methylation. Cell. 2017;171:877–99. https://doi.org/10.1016/j.cell.2017.09.003.

53. Nainar S, Marshall PR, Tyler CR, Spittle RC, Bredy TW. Evolving insights into RNA modifications and their functional diversity in the brain. Nat Neurosci. 2016;19:1292–8. https://doi.org/10.1038/nn.4378.

54. Chen J, Wang X, Fei W, Fang X, Hu X. Epitranscriptomic m6A modification in the stem cell field and its effects on cell death and survival. Am J Cancer Res. 2019;9:752–64.

55. Engel M, Chen A. The emerging role of mRNA methylation in normal and pathological behavior. Genes Brain Behav. 2018;17:e12428. https://doi.org/10.1111/gbb.12428.

56. Ji P, Wang X, Xie N, Li Y. N6-methyladenosine in RNA and DNA: an epitranscriptomic and epigenetic player implicated in determination of stem cells fate. Stem Cells Int. 2018;2018:3256524. https://doi.org/10.1155/2018/3256524.

57. Noack F, Argenti C, Bazzucchi M, Emiliani C, Martino S. Above the epitranscriptome: RNA modifications and stem cell identity. Genes. 2018. https://doi.org/10.3390/genes9070329.

58. Chen J, Wang X, Hu X. Epitranscriptomic m6A modification in the stem cell field and its effects on cell death and survival. Am J Cancer Res. 2019;9:752–64.

59. Geula S, Moshitch-Moshkovitz S, Dominissini D, Mansour AA, Kol N, Salmon-Dixon M, et al. Stem cells. m6A mRNA methylation facilitates resolution of naive pluripotency toward differentiation. Science. 2015;347:1002–6. https://doi.org/10.1126/science.1261417.

60. Nainar S, Marshall PR, Tyler CR, Spittle RC, Bredy TW. Evolving insights into RNA modifications and their functional diversity in the brain. Nat Neurosci. 2016;19:1292–8. https://doi.org/10.1038/nn.4378.

61. Geissler R, Simkin A, Floss D, Patel R, Fogarty EA, Scheller J, et al. A widespread sequence-specific mRNA decay pathway mediated by hnRNP A1 and A2/B1. Genes Dev. 2016;30:1070–85. https://doi.org/10.1101/gad.170732.116.

62. Liu N, Zhou KJ, Parisien M, Dai Q, Diatchenko L, Pan T. N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein. Nucleic Acids Res. 2017;45:6051–63. https://doi.org/10.1093/nar/gkx411.

63. Huang H, Wang H, Sun W, Qin X, Shi Y, Wu H, et al. Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20:285–95. https://doi.org/10.1038/s41556-018-0045-z.

64. Wu R, Li A, Sun B, Sun JG, Zhang J, Zhang T, et al. A novel m6A reader Prc2a controls oligodendroglial specification and myelination. Cell Res. 2018;28:23–41. https://doi.org/10.1038/s41422-018-0113-8.

65. Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Dixon M, Ungar L, Osenberg S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485:201–6. https://doi.org/10.1038/nature11112.

66. Chang M, Lv H, Zhang W, Ma C, He X, Zhao S, et al. Region-specific RNA m6A methylation represents a new layer of control in the gene regulatory network in the mouse brain. Open Biol. 2017. https://doi.org/10.1098/rsob.170166.

67. Noack F, Calegari F. Epitranscriptomics: a new regulatory mechanism of brain development and function. Front Neurosci. 2018;12:85. https://doi.org/10.3389/fnins.2018.00085.

68. Batista PJ, Molline B, Wang J, Qu K, Zhang J, Li L, et al. m6A RNA modification controls cell fate transition in mammalian embryonic stem cells. Cell Stem Cell. 2014;15:707–19. https://doi.org/10.1016/j.stem.2014.09.019.

69. Liu J, Harada BT, He C. Regulation of gene expression by N6-methyladenosine in cancer. Trends Cell Biol. 2019;29:487–99. https://doi.org/10.1016/j.tcb.2019.02.008.

70. Marty A, Das B. N6-methyladenosine modification in mRNA: machinery, function and implications for health and diseases. FEBS J. 2016;283:1607–30. https://doi.org/10.1111/febs.13614.

71. Davis Y, Zeng W, Fang X, Hu X. Epitranscriptomic m6A modification in the stem cell field and its effects on cell death and survival. Am J Cancer Res. 2019;9:752–64.

72. Engel M, Chen A. The emerging role of mRNA methylation in normal and pathological behavior. Genes Brain Behav. 2018;17:e12428. https://doi.org/10.1111/gbb.12428.
82. Chen X, Yu C, Guo M, Zheng X, Ali S, Huang H, et al. Down-regulation of m6A RNA methylation is involved in dopaminergic neuronal death. ACS Chem Neurosci. 2019;10:2353–63. https://doi.org/10.1021/acschemneuro.8b00857.

83. Zhang Z, Wang M, Xi D, Huang Z, Zhang L, Yang Y, et al. METTL3-mediated N6-methyladenosine mRNA modification enhances long-term memory consolidation. Cell Res. 2018;28:1050–61. https://doi.org/10.1038/s41422-018-0092-9.

84. Koranda JL, Dore L, Shi H, Patel MJ, Vaasjo LO, Rao MN, et al. Mettl14 is essential for epitranscriptomic regulation of striatal function and learning. Neuron. 2019;98:283–92. https://doi.org/10.1016/j.neuron.2018.06.007.

85. Hess ME, Hess S, Meyer KD, Verhagen LA, Koch L, Brönneke HS, et al. The fat mass and obesity associated gene (Fto) regulates activity of the dopaminergic midbrain circuitry. Nat Neurosci. 2013;16:1042–8. https://doi.org/10.1038/nn.3449.

86. Bai L, Tang Q, Zou Z, Meng P, Tu B, Xia L, et al. m6A demethylase FTO regulates dopaminergic neurotransmission deficits caused by arsenite. Toxicol Sci. 2018;165:431–46. https://doi.org/10.1093/toxsci/kfy172.

87. Walters BJ, Mercaldo V, Gillon CJ, Yip M, Neve RL, Boyce FM, et al. The role of the m6A demethylase FTO (fat mass and obesity-associated) and m6A methylation in hippocampal memory formation. Neuropsychopharmacology. 2017;42:1002–10. https://doi.org/10.1038/npp.2017.31.

88. Widagdo J, Zhao QY, Kempen AJ, Tan MC, Ratnu VS, Wei W, et al. Experience-dependent accumulation of N6-methyladenosine in the prefrontal cortex is associated with memory processes in mice. J Neurosci. 2016;36:6771–7. https://doi.org/10.1523/JNEUROSCI.4053-15.2016.

89. Engel M, Eggert C, Kaplick PM, Eder M, Roh S, Tietze L, et al. The role of m6A/mRNA methylation in stress response regulation. Neuron. 2018;99:389–403. https://doi.org/10.1016/j.neuron.2018.07.009.

90. Li L, Zhang L, Zhang F, Chen J, Shen H, Shi L, et al. Fat mass and obesity-associated (Fto) protein regulates adult neurogenesis. Hum Mol Genet. 2017;26:2398–411. https://doi.org/10.1093/hmg/ddx128.

91. Shi H, Zhang X, Weng YL, Lu Z, Liu Y, Lu Z, et al. m6A facilitates hippocampus-dependent learning and memory through YTHDF1. Nature. 2018;563:249–53. https://doi.org/10.1038/s41586-018-0666-1.

92. Ma C, Chang M, Lv H, Zhang ZW, Zhang W, He X, et al. RNA m 6 A methylation participates in regulation of postnatal development of the mouse cerebellum. Genome Biol. 2018;19:68. https://doi.org/10.1186/s13059-018-1435-z.

93. Frye M, Harada BT, Behm M, He C. RNA modifications modulate gene expression during development. Science. 2018;361:1346–9. https://doi.org/10.1126/science.aau1646.

94. Wang CX, Cui GS, Liu X, Xu K, Wang M, Zhang XX, et al. METTL3-mediated m6A modification is required for cerebellar development. PLoS Biol. 2018;16:e2004880. https://doi.org/10.1371/journal.pbio.2004880.

95. Fu Y, Zorman B, Sumazin P, Sanna PP, Repeunte-Canonigo V. Epitranscriptomics: correlation of N6-methyladenosine RNA methylation and pathway dysregulation in the hippocampus of HIV transgenic rats. PLoS ONE. 2019;14:e0203566. https://doi.org/10.1371/journal.pone.0203566.

96. Merkurjev D, Hong WT, Iida K, Oomoto I, Goldie BJ, Yamagishi H, et al. Synthetic N6-methyladenosine (m6A) epitranscriptome reveals functional partitioning of localized transcripts. Nat Neurosci. 2018;21:1004–14. https://doi.org/10.1038/s41593-018-0173-6.

97. Weng YL, Wang X, An R, Cassin J, Wisers C, Liu Y, et al. Epitranscriptomic m6A regulation of axon regeneration in the adult mammalian nervous system. Neuron. 2018;97:313–25. https://doi.org/10.1016/j.neuron.2017.12.036.

98. Yu J, Chen M, Huang H, Zhu J, Song H, Zhu J, et al. Dynamic m6A modification regulates local translation of mRNA in axons. Nucleic Acids Res. 2016;44:4142–23. https://doi.org/10.1093/nar/gkw1182.

99. Zhuang M, Li X, Zhu J, Zhang J, Niu F, Liang F, et al. The m6A reader YTHDF1 regulates axon guidance through translational control of Robo3.1 expression. Nucleic Acids Res. 2019;47:7475–77. https://doi.org/10.1093/nar/gkz157.

100. Chai RC, Wu F, Wang QX, Zhang S, Zhang RN, Liu YQ, et al. m6A RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gliomas. Aging. 2018;11:1204–25. https://doi.org/10.18632/aging.101829.
118. Melka MG, Gillis J, Bernard M, Abramowicz M, Chakravarty MM, Leonard GT, et al. FTO, obesity and the adolescent brain. Hum Mol Genet. 2010;22:1050–8. https://doi.org/10.1093/hmg/ddq504.

119. Choudhry Z, Sengupta SM, Grizenko N, Thakur GA, Forter ME, Schmitz N, et al. Association between obesity-related gene FTO and ADHD. Obesity. 2013;21:e738–44. https://doi.org/10.1002/oby.20444.

120. Keller L, Xu W, Wang HX, Winblad B, Fratiglioni L, Graff C. The obesity related gene, FTO, interacts with APOE, and is associated with Alzheimer’s disease risk: a prospective cohort study. J Alzheimers Dis. 2011;23:461–9. https://doi.org/10.3233/JAD-2010-101068.

121. Reitz C, Tosto G, Mayeux R, Luchsinger JA, et al. Genetic variants in the fat and obesity associated (FTO) gene and risk of Alzheimer’s disease. PLoS ONE. 2012;7:e50354. https://doi.org/10.1371/journal.pone.0050354.

122. Li H, Ren Y, Mao K, Hua F, Yang Y, Wei N, et al. FTO is involved in Alzheimer’s disease by targeting TSC1-mTOR-Tau signaling. Biochem Biophys Res Commun. 2018;498:234–9. https://doi.org/10.1016/j.bbrc.2018.02.201.

123. Samaan Z, Anand SS, Zhang X, Desai D, Rivera M, Pare G, et al. The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression. Mol Psychiatry. 2013;18:1281–6. https://doi.org/10.1038/mp.2012.160.

124. Rivera M, Locke AE, Corre T, Czamara D, Wolf C, Ching-Lopez A, et al. Interaction between the FTO gene, body mass index and depression: meta-analysis of 13701 individuals. Br J Psychiatry. 2017;211:70–6. https://doi.org/10.1192/bjp.bp.116.183475.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.